Riccardo Mazza: Do Weight, BMI, and Renal Function Independently Predict Acute Events in NVAF Patients on DOACs?
Riccardo Mazza, Cardiology Resident at University Vita-Salute San Raffaele, shared a post on LinkedIn about a recent article and his colleagues co-authored, adding:
“DOACs: Not weight.
Not renal function.
It’s plasma levels.
In our latest research letter, we addressed a key clinical question:
Do weight, BMI, and renal function independently predict acute events in NVAF patients on DOACs?
Short answer: they do not – once drug exposure is accounted for.
Our findings suggest a mediated effect: renal function influences outcomes through modulation of DOAC plasma levels, rather than acting as an independent determinant.
Clinical implications:
Weight and renal function remain essential for dose selection.
However, when it comes to actual patient risk, the key determinant may be:
- true pharmacological exposure
In other words:
We dose based on patient characteristics – but outcomes are driven by drug levels.
Link to the Research Letter in the first comment.
Grateful to the entire team Cosmo Godino, Carlo Gaspardone, Anna Salerno, Massimo Slavich, Rachele Sena.”
Title: Beyond Weight and Renal Function: DOAC Plasma Levels Remain the Primary Determinant of Acute Outcomes—A Re-Analysis of the 4Levels Study
Authors: Riccardo Mazza, Carlo Gaspardone, Chiara Miranda, Sofia Di Bisceglie, Alessia Minerva, Rachele Sena, Gianmarco Cozzani, Anna Salerno, Michela Cera, Massimo Slavich, Leila Anna De Lorenzo, Giulio Leo, Giulia Nemola, Annalisa Fattorini, Luciano Crippa, Patrizia Della Valle, Alberto Margonato, Armando D’Angelo, Cosmo Godino
Read the Full Article on Clinical Therapeutics
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 8, 2026, 14:17Chokri Ben Lamine: Anticoagulation Switching Pearls
-
Apr 8, 2026, 14:13Francisco Chacón-Lozsán: Bleeding on Anticoagulation Is Not a Complication, It’s a Turning Point
-
Apr 8, 2026, 07:32Giulia Simini: Acquired von Willebrand Syndrome and Coagulation Abnormalities in MPN-Associated Thrombocytosis
-
Apr 8, 2026, 07:14Julian Kyoung-Ryul Chun: Join the Discussion at EHRA 2026
-
Apr 8, 2026, 06:41Stephanie Diez de Sollano: Why Ehlers-Danlos Syndrome Deserves More Attention
-
Apr 7, 2026, 19:17Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
-
Apr 7, 2026, 19:07Clara Meijs: Great Time Presenting Our Endometriosis Project at the AHA EPI Lifestyle Conference
-
Apr 7, 2026, 18:18Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
-
Apr 7, 2026, 17:44Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine